Abnormal eyeblink conditioning is an early marker of cerebellar dysfunction in preclinical SCA3 mutation carriers.


Journal

Experimental brain research
ISSN: 1432-1106
Titre abrégé: Exp Brain Res
Pays: Germany
ID NLM: 0043312

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 03 08 2018
accepted: 01 11 2018
pubmed: 16 11 2018
medline: 4 6 2019
entrez: 16 11 2018
Statut: ppublish

Résumé

Spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited degenerative diseases. As the pathological process probably commences years before the first appearance of clinical symptoms, preclinical carriers of a SCA mutation offer the opportunity to study the earliest stages of cerebellar dysfunction and degeneration. Eyeblink classical conditioning (EBCC) is a motor learning paradigm, crucially dependent on the integrity of the olivocerebellar circuit, and has been shown to be able to detect subtle alterations of cerebellar function, which might already be present in preclinical carriers. In order to acquire conditioned responses, we performed EBCC, delay paradigm, in 18 preclinical carriers of a SCA3 mutation and 16 healthy, age-matched controls by presenting repeated pairings of an auditory tone with a supraorbital nerve stimulus with a delay interval of 400 ms. Preclinical carriers acquired significantly less conditioned eyeblink responses than controls and learning rates were significantly reduced. This motor learning defect was, however, not associated with the predicted time to onset. EBCC is impaired in preclinical carriers of a SCA3 mutation, as a result of impaired motor learning capacities of the cerebellum and is thus suggestive of cerebellar dysfunction. EBCC can be used to detect but probably not monitor preclinical cerebellar dysfunction in genetic ataxias, such as SCA3.

Sections du résumé

BACKGROUND BACKGROUND
Spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited degenerative diseases. As the pathological process probably commences years before the first appearance of clinical symptoms, preclinical carriers of a SCA mutation offer the opportunity to study the earliest stages of cerebellar dysfunction and degeneration. Eyeblink classical conditioning (EBCC) is a motor learning paradigm, crucially dependent on the integrity of the olivocerebellar circuit, and has been shown to be able to detect subtle alterations of cerebellar function, which might already be present in preclinical carriers.
METHODS METHODS
In order to acquire conditioned responses, we performed EBCC, delay paradigm, in 18 preclinical carriers of a SCA3 mutation and 16 healthy, age-matched controls by presenting repeated pairings of an auditory tone with a supraorbital nerve stimulus with a delay interval of 400 ms.
RESULTS RESULTS
Preclinical carriers acquired significantly less conditioned eyeblink responses than controls and learning rates were significantly reduced. This motor learning defect was, however, not associated with the predicted time to onset.
CONCLUSIONS CONCLUSIONS
EBCC is impaired in preclinical carriers of a SCA3 mutation, as a result of impaired motor learning capacities of the cerebellum and is thus suggestive of cerebellar dysfunction. EBCC can be used to detect but probably not monitor preclinical cerebellar dysfunction in genetic ataxias, such as SCA3.

Identifiants

pubmed: 30430184
doi: 10.1007/s00221-018-5424-y
pii: 10.1007/s00221-018-5424-y
pmc: PMC6373441
doi:

Substances chimiques

Repressor Proteins 0
ATXN3 protein, human EC 3.4.19.12
Ataxin-3 EC 3.4.19.12

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

427-433

Subventions

Organisme : Jacques und Gloria Gossweiler-Stiftung
ID : x

Références

Behav Neurosci. 2002 Feb;116(1):22-36
pubmed: 11895180
Brain. 2003 Jan;126(Pt 1):71-94
pubmed: 12477698
Behav Neurosci. 1992 Dec;106(6):879-88
pubmed: 1335267
J Neurosci. 1992 Nov;12(11):4403-26
pubmed: 1432102
Science. 2003 Sep 19;301(5640):1736-9
pubmed: 14500987
Learn Mem. 2003 Sep-Oct;10(5):337-45
pubmed: 14557606
Lancet Neurol. 2004 May;3(5):291-304
pubmed: 15099544
Exp Brain Res. 2005 Apr;162(3):332-45
pubmed: 15586270
Psychophysiology. 2005 Jan;42(1):1-15
pubmed: 15720576
Ann Neurol. 2005 Apr;57(4):505-12
pubmed: 15747371
J Neurosci. 2005 Apr 13;25(15):3919-31
pubmed: 15829644
Neurology. 2006 Jun 13;66(11):1717-20
pubmed: 16769946
Neurosci Lett. 2006 Oct 2;406(1-2):87-91
pubmed: 16905257
J Neurosci. 2007 Mar 7;27(10):2493-502
pubmed: 17344387
Brain Res. 2008 Mar 10;1198:73-84
pubmed: 18262502
Neuroscience. 2009 Sep 1;162(3):787-96
pubmed: 19162131
Neuroscience. 2009 Sep 1;162(3):732-55
pubmed: 19409234
Behav Brain Res. 2010 Oct 15;212(2):143-51
pubmed: 20385171
Neuron. 2011 Apr 14;70(1):43-50
pubmed: 21482355
Cerebellum. 2012 Sep;11(3):749-60
pubmed: 22198871
J Physiol. 2012 Feb 15;590(4):887-97
pubmed: 22199171
Cerebellum. 2013 Aug;12(4):493-503
pubmed: 23389921
Cephalalgia. 2014 Oct;34(11):904-13
pubmed: 24567118
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14930-4
pubmed: 25267641
J Neurosci. 2015 Jan 21;35(3):1228-39
pubmed: 25609637
Brain. 2015 May;138(Pt 5):1182-97
pubmed: 25818870
Neurology. 2015 Jul 7;85(1):96-103
pubmed: 26062625
Cereb Cortex. 2016 Jul;26(7):3205-18
pubmed: 26209844
Cell Rep. 2015 Dec 1;13(9):1741-6
pubmed: 26655894
Cell Rep. 2015 Dec 1;13(9):1977-88
pubmed: 26655909
Neuropsychologia. 2016 May;85:287-300
pubmed: 27020135
Neuropsychologia. 2018 Aug;117:551-557
pubmed: 30031016
Exp Brain Res. 1986;63(1):158-62
pubmed: 3015653
Exp Brain Res. 1985;60(1):114-26
pubmed: 4043270
Science. 1984 Jan 20;223(4633):296-9
pubmed: 6701513
J Neurosci. 1993 Apr;13(4):1708-18
pubmed: 8463846

Auteurs

J van Gaalen (J)

Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.

R P P W M Maas (RPPWM)

Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.

E F Ippel (EF)

Department of Medical Genetics, University Medical Center, Utrecht, The Netherlands.

M W Elting (MW)

Department of Genetics, VU University Medical Center, Amsterdam, The Netherlands.

K Y van Spaendonck-Zwarts (KY)

Department of Genetics, Academic Medical Center, Amsterdam, The Netherlands.

S Vermeer (S)

Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands.

C Verschuuren-Bemelmans (C)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

D Timmann (D)

Department of Neurology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Bart P van de Warrenburg (BP)

Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. bart.vandewarrenburg@radboudumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH